HEM.V - Hemostemix Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0450
+0.0100 (+28.57%)
At close: 12:14PM EDT
Stock chart is not supported by your current browser
Previous Close0.0350
Open0.0400
Bid0.0450 x 0
Ask0.0500 x 0
Day's Range0.0400 - 0.0450
52 Week Range0.0350 - 0.1400
Volume74,000
Avg. Volume55,684
Market Cap13.54M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire7 days ago

    Hemostemix Announces Financing Update and Interim CFO Appointment

    OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces that due to market conditions, it will not be proceeding with its previously announced non-brokered private placement of up to a maximum of $6,000,000 principal amount of secured convertible debentures.  In addition, the Company would like to announce that it will not be having a second closing of its non-brokered private placement of up to a maximum of $1,000,000 principal amount of secured convertible debentures.

  • GlobeNewswire16 days ago

    Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery

    OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to announce that it’s abstract was accepted at the upcoming 41st Annual Canadian Society for Vascular Surgery Meeting. The abstract is entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup” by lead investigator Dr. York Hsiang, Professor of Vascular Surgery, University of British Columbia.

  • GlobeNewswire21 days ago

    Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial

    As previously announced, the Company has been working closely with its trial sites over the past few months to advance patient enrollment.  In the past several weeks, seven (7) additional patients have been enrolled and treated under the Company’s CLI clinical trial protocol.  This total of 40 patients that have been treated to date represent over 42% of the total trial enrollment goal. The Company currently has fourteen (14) trial sites open, of which twelve are located in the United States and two in Canada, that are actively screening patients for enrollment in the study.

  • GlobeNewswire23 days ago

    Hemostemix Announces Resignation of CFO

    The Company has commenced the search for a suitable replacement and will announce Ms. Gulka’s replacement in due course. Ms. Gulka has agreed to provide accounting services to the Company until July 4, 2019 as it searches for a new CFO.  Management and the board of directors would like to thank Ms. Gulka for her contributions to the Company this past year and wish her well in her future endeavors.

  • GlobeNewswire2 months ago

    Hemostemix Closes First Tranche of Financing

    As previously announced, each debenture consists of $1,000 aggregate principal amount of secured, non-transferable, convertible, redeemable debentures (the “Debentures”), maturing on December 31, 2019 (the "Maturity Date”) and bear interest at a rate of 12% per annum. The principal amount of the Debentures is convertible into common shares of the Company (“Common Shares”) at the option of the holder at a price of $0.055 per Common Share.

  • GlobeNewswire2 months ago

    Hemostemix Announces Convertible Debenture Financing

    Each debenture will consist of $1,000 aggregate principal amount of secured, non-transferable, convertible, redeemable debentures (the “Debentures”). The Debentures will mature on December 31, 2019 (the "Maturity Date”) and bear interest at a rate of 12% per annum.

  • GlobeNewswire3 months ago

    Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial

    Enrollment rates have increased substantially over the past several weeks, with an additional nine (9) patients enrolled and treated under the Company’s CLI clinical trial protocol.  A total of thirty-three (33) patients have been treated to date, representing over one third of the total trial enrollment goal. The Company currently has twelve (12) trial sites open, of which eleven are located in the United States and one in Vancouver, Canada, that are actively screening patients for enrollment in the study.  The Company has additional clinical trial sites starting up in Canada and the United States.

  • GlobeNewswire4 months ago

    Hemostemix Announces Appointment of Experienced Chief Medical Officer & President

    OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D, Ph.D. has been appointed the Company’s President and Chief Medical Officer.  Dr. Jacobs previously acted as a medical consultant to the Company.  Dr. Jacobs takes over the role of President from Kyle Makofka who remains as the Company’s Chief Executive Officer.

  • GlobeNewswire5 months ago

    Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial

    UC Davis Medical Center brings state-of-the-art vascular care to patients throughout Central and Northern California. The Division of Vascular Surgery at UC Davis Medical Center has grown to become the largest vascular specialty group in the region.

  • GlobeNewswire5 months ago

    Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA

    OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, is pleased to announce that it has submitted an application with the US Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (”ODD”) status for its lead product ACP-01 for the treatment of critical limb ischemia (“CLI”).

  • GlobeNewswire6 months ago

    Hemostemix Provides Highlights of 2018 Accomplishments

    CALGARY, Alberta, Jan. 17, 2019 -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Hemostemix, Fennec Pharmaceuticals, Sernova and Covalon Technologies

    NEW YORK, NY / ACCESSWIRE / January 10, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire6 months ago

    Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial

    OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”).  In addition, the Company is pleased to provide an update on patient enrollment in the trial. Medical University of South Carolina is located in Charleston, South Carolina, USA with Dr. Thomas E. Brothers, MD as the principal investigator.  Dr. Brothers is a vascular surgeon who focuses on management of circulation and peripheral vascular disease and has been recognized as one of America’s top surgeons and best doctors since 2003.  Founded in 1824, the Medical University of South Carolina (“MUSC”) educates and trains more than 3,000 students and 700 residents in six colleges and has nearly 13,000 employees, including approximately 1,500 faculty members.  MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the NCI-designated Hollings Cancer Center, a Level I trauma centre and South Carolina’s only transplant center.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Microbix Biosystems, Hemostemix, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire8 months ago

    Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors

    OTCQB: HMTXF) is pleased to provide the following update on its research and development activities.  Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and refinements to its manufacturing process, the Company is pleased to announce it has made additional findings surrounding its overall technology platform and initiation of R&D work on NCP-01, another one of its product pipeline candidates. As disclosed in its recent press release, the Company has been furthering its research and development (“R&D”) initiatives with a focus on optimizing the manufacturing process of ACP-01, with an underlying focus on continuing to expand the potential of the Company’s technology platform.

  • ACCESSWIRE9 months ago

    Today's Research Reports on CardioComm Solutions, Sernova, Hemostemix and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 25, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Hemostemix, TSO3, Emerald Health Therapeutics and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE11 months ago

    Today's Research Reports on Centric Health, Hemostemix, CardioComm Solutions and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRElast year

    Today's Research Reports on Hemostemix, Cotinga Pharmaceuticals, Emerald Health Therapeutics and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...